USD 0.08
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -169.7 Million USD | 4.69% |
2022 | -178.05 Million USD | 54.5% |
2021 | -391.3 Million USD | -35.75% |
2020 | -288.26 Million USD | -79.97% |
2019 | -160.17 Million USD | 17.62% |
2018 | -194.43 Million USD | -7.41% |
2017 | -181.01 Million USD | 6.65% |
2016 | -193.91 Million USD | -15.23% |
2015 | -168.27 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q3 | -227.67 Million USD | -2104352.83% |
2024 Q1 | -212.87 Million USD | -25.44% |
2024 Q2 | -163.15 Million USD | 23.36% |
2023 Q3 | -112.59 Million USD | -87.43% |
2023 FY | -169.7 Million USD | 4.69% |
2023 Q2 | -60.07 Million USD | 64.89% |
2023 Q1 | -171.09 Million USD | 3.91% |
2023 Q4 | -169.7 Million USD | -50.71% |
2022 Q4 | -178.05 Million USD | 10.45% |
2022 FY | -178.05 Million USD | 54.5% |
2022 Q3 | -198.83 Million USD | 15.49% |
2022 Q1 | -386.94 Million USD | 1.12% |
2022 Q2 | -235.27 Million USD | 39.2% |
2021 Q1 | -310.98 Million USD | 0.0% |
2021 FY | -391.3 Million USD | -35.75% |
2021 Q3 | -344.97 Million USD | -31.83% |
2021 Q4 | -391.3 Million USD | -13.43% |
2021 Q2 | -261.68 Million USD | 15.85% |
2020 FY | -288.26 Million USD | -79.97% |
2019 FY | -160.17 Million USD | 17.62% |
2018 FY | -194.43 Million USD | -7.41% |
2017 FY | -181.01 Million USD | 6.65% |
2016 FY | -193.91 Million USD | -15.23% |
2015 FY | -168.27 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
AstraZeneca PLC | 22.74 Billion USD | 100.746% |
Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 100.566% |
CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 89.354% |
Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 1170.402% |
Novartis AG | 12.95 Billion USD | 101.31% |